Treatment of early episode in patients with schizophrenia: The role of long acting antipsychotics

European Psychiatry

Volumn 29, Issue S2, 2014, Pages 1409-1413

  Heres, S ^a   Lambert, M ^b   Vauth, R ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antipsychotic; First episode; Long acting injections; Recent onset; Schizophrenia

Indexed keywords

LONG ACTING DRUG; LONG ACTING INJECTABLE ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; RISPERIDONE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION;

CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; DIRECTLY OBSERVED THERAPY; GLOBAL ASSESSMENT OF FUNCTIONING; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; MENTAL HEALTH CARE; PATIENT SELECTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PROGNOSIS; PSYCHOEDUCATION; QUALITY OF LIFE; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; SCHIZOPHRENIA; ADMINISTRATION AND DOSAGE; DELAYED RELEASE FORMULATION; INJECTION; PHARMACOLOGY;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS; MEDICATION ADHERENCE; SCHIZOPHRENIA;

EID: 84912574262     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/S0924-9338(14)70001-X     Document Type: Review

References (73)

1. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999, 56:241-247.
2. Chien WT, Yip AL Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments. Neuropsychiatr Dis Treat 2013, 9:1311-1332.
3. Leucht S, Zhao J Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. J Psychopharmacol 2014, 28:387-394.
4. Johnson DA Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 1984, 45:13-21.
5. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L Depot antipsychotic drugs. Place in therapy. Drugs 1994, 47:741-773.
6. Barnes TR, Curson DA Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994, 10:464-479.
7. Stahl SM Long-acting injectable antipsychotics: shall the last be first?. CNS Spectr 2014, 19:3-5.
8. Emsley R, Chiliza B, Asmal L, Mashile M, Fusar-Poli P Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry 2013, 7:247-254.
9. Taylor M, Ng KY Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust N Z J Psychiatry 2013, 47:624-630.
10. Altamura AC, Aguglia E, Bassi M, Bogetto F, Cappellari L, De Giorgi S, et al. Rethinking the role of long-acting atypical antipsychotics in the community setting. Int Clin Psychopharmacol 2012, 27:336-349.
11. Jaeger M, Rossler W Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 2010, 175:58-62.
12. Heres S, Reichhart T, Hamann J, Mendel R, Leucht S, Kissling W Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry 2011, 26:297-301.
13. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011, 168:603-609.
14. Birchwood M, Todd P, Jackson C Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998, 172:53-59.
15. Cassidy CM, Norman R, Manchanda R, Schmitz N, Malla A Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull 2010, 36:1001-1008.
16. Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013, 39:1296-1306.
17. Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 2012, 73:e541-e547.
18. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2012, 5. CD008016.
19. Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996, 14:13S-21S.
20. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998, 24:75-85.
21. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001, 50:884-897.
22. Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res 2012, 134:219-225.
23. Zipursky RB, Menezes NM, Streiner DL Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 2014, 152:408-414.
24. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001, 158:1835-1842.
25. Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010, 341:c4024.
26. Kane JM Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 2007, 68(Suppl 14):27-30.
27. Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Lancet 2009, 373:408-415.
28. Almond S, Knapp M, Francois C, Toumi M, Brugha T Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004, 184:346-351.
29. Awad AG, Voruganti LN The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008, 26:149-162.
30. Law MR, Soumerai SB, Ross-Degnan D, Adams AS A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008, 69:47-53.
31. Kane JM Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success. J Clin Psychiatry 2013, 74:e18.
32. Weiden PJ, Olfson M Cost of relapse in schizophrenia. Schizophr Bull 1995, 21:419-429.
33. Dolder CR, Lacro JP, Dunn LB, Jeste DV Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am J Psychiatry 2002, 159:103-108.
34. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004, 65:354-360.
35. Nakonezny PA, Byerly MJ Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophr Res 2006, 82:107-114.
36. Ucok A, Polat A, Cakir S, Genc A One year outcome in first episode schizophrenia. Predictors of relapse. Eur Arch Psychiatry Clin Neurosci 2006, 256:37-43.
37. Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 2012, 139:116-128.
38. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
39. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
40. Acosta FJ, Hernandez JL, Pereira J, Herrera J, Rodriguez CJ Medication adherence in schizophrenia. World J Psychiatry 2012, 2:74-82.
41. Higashi K, Medic G, Littlewood KJ, Diez T, Granstrom O, De Hert M Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 2013, 3:200-218.
42. Macaluso M, McKnight S Overcoming medication nonadherence in schizophrenia: Strategies that can reduce harm. Current Psychiatry 2013, 12:14-20.
43. Acosta FJ, Bosch E, Sarmiento G, Juanes N, Caballero-Hidalgo A, Mayans T Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res 2009, 107:213-217.
44. Hui CL, Chen EY, Kan CS, Yip KC, Law CW, Chiu CP Detection of non-adherent behaviour in early psychosis. Aust N Z J Psychiatry 2006, 40:446-451.
45. Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006, 32:724-742.
46. Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ 2014, 348:g1173.
47. Emsley R, Chiliza B, Asmal L, de Fleuriot M Long acting injectable antipsychotics in early psychosis. Antipsychotic long-acting injections 2010, 145-162. Oxford University Press, Oxford. P. Haddad, T. Lambert, J. Lauriello (Eds.).
48. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007, 68:1751-1762.
49. Malla A, Tibbo P, Chue P, Levy E, Manchanda R, Teehan M, et al. Long-acting injectable antipsychotics: recommendations for clinicians. Can J Psychiatry 2013, 58:30S-35S.
50. Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 2013, 13:340.
51. West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008, 34:995-1001.
52. Potkin S, Bera R, Zubek D, Lau G Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 2013, 13:261.
53. Heres S, Hamann J, Kissling W, Leucht S Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006, 67:1948-1953.
54. Heres S, Hamann J, Mendel R, Wickelmaier F, Pajonk FG, Leucht S, et al. Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1987-1993.
55. Samalin L, Charpeaud T, Blanc O, Heres S, Llorca PM Clinicians' attitudes toward the use of long-acting injectable antipsychotics. J Nerv Ment Dis 2013, 201:553-559.
56. Hamann J, Kissling W, Heres S Checking the plausibility of psychiatrists arguments for not prescribing depot medication. Eur Neuropsychopharmacol 2014, 24:1506-1510.
57. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009, 70:1397-1406.
58. Kaplan G, Casoy J, Zummo J Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence 2013, 7:1171-1180.
59. Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1231-1235.
60. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa-McMillan A Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study. J Clin Psychiatry 2012, 73:1224-1233.
61. Malla A, Chue P, Jordan G, Stip E, Koczerginski D, Milliken H, et al. An Exploratory Open-Label Randomized Trial Comparing Risperidone Long Acting Injectable (RLAI) with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clin Schizophr Relat Psychoses 2013, 1-26.
62. Csernansky JG, Mahmoud R, Brenner R A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002, 346:16-22.
63. Bartzokis G, Lu PH, Amar CP, Raven EP, Detore NR, Altshuler LL, et al. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res 2011, 132:35-41.
64. Bartzokis G, Lu PH, Raven EP, Amar CP, Detore NR, Couvrette AJ, et al. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res 2012, 140:122-128.
65. Adams CE, Fenton MK, Quraishi S, David AS Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001, 179:290-299.
66. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011, 127:83-92.
67. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013, 74:957-965.
68. Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013, 74:568-575.
69. Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, et al. Does long-acting injectable risperidone make a difference to the reallife treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 2012, 134:187-194.
70. Kane JM, Kishimoto T, Correll CU Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol 2013, 66:S37-S41.
71. Manchanda R, Chue P, Malla A, Tibbo P, Roy MA, Williams R, et al. Long-acting injectable antipsychotics: evidence of effectiveness and use. Can J Psychiatry 2013, 58:5S-13S.
72. Tiihonen J, Wahlbeck K, Lonnqvist J, Klaukka T, Ioannidis JP, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006, 333:224.
73. Ventura J, Subotnik KL, Guzik LH, Hellemann GS, Gitlin MJ, Wood RC, et al. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res 2011, 132:18-23.